Resultados de la búsqueda 161-170 of 1014 for Alternative

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  2. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  10. Medicina cardiovascular - Ensayos clínicos - Mayo Clinic

    Finally, it will allow characterization of patient selection factors and processes for ticagrelor vs alternative OAP agents, carrying out that descriptive ...